No treatment available anywhere in the world reliably switches tinnitus off. That is the position of the international expert panel that reviewed the state of the field in 2024, which put it plainly: no treatment can reliably eliminate tinnitus or reduce its loudness, which is what most patients want. No medicine is approved for tinnitus by the TGA, the FDA or the European regulators.
A second question matters more day-to-day, and it has a measurable answer. Can tinnitus stop dominating your sleep, concentration, and mood? In good-quality trials, roughly half of people who receive structured care record a clinically meaningful drop in how much tinnitus affects them, and in some treatment programs the figure is higher. The distinction between silencing tinnitus and defusing it runs through everything below.
What counts as success in tinnitus research
Two questionnaires carry most of the evidence. The Tinnitus Handicap Inventory (THI) and the Tinnitus Functional Index (TFI) both score from 0 to 100 and both measure the effect tinnitus has on sleep, concentration, emotion and daily function. A 7-point fall on the THI, or 13 points on the TFI, is commonly used as a research threshold for clinically meaningful improvement, although estimates vary between studies. These thresholds are used for the response rates quoted in this article.
Loudness is rarely the primary outcome for practical reasons. Matching tinnitus pitch and loudness in a booth produces unreliable numbers, so trials measure handicap instead. When a study reports that 80% of participants responded, it means 80% crossed a handicap threshold. It does not mean their tinnitus went quiet, and it does not mean it disappeared.
How common tinnitus is, and how many people are badly affected
A 2022 meta-analysis in JAMA Neurology pooled 83 prevalence studies and 12 incidence studies. Tinnitus of any kind affects 14.4% of adults, chronic tinnitus 9.8%, and diagnosed tinnitus 3.4%. Severe tinnitus affects 2.3% of adults, which the authors translate to roughly 120 million people worldwide out of 749 million with symptoms of any severity. Prevalence climbs with age, from 9.7% in adults aged 18 to 44, to 13.7% at 45 to 64, to 23.6% past 65. About 1% of the population develops new cases each year.
Australian figures come from a survey of 4,970 working adults published in the Medical Journal of Australia in 2022. Tinnitus of some form was reported by 26.5% of respondents, and constant tinnitus by 5.5%, higher in men (7.5%) than women (3.3%) and rising to 11.7% in workers aged 55 to 64. Occupation mattered: constant tinnitus was estimated at 16.7% among automotive workers, 13.0% among drivers and 12.1% among farmers.
Tinnitus that can be stopped
A minority of tinnitus has a cause that can be removed, and those cases are the closest thing to a cure.Earwax blockage, middle ear fluid, and eardrum problems can cause tinnitus that settles once the ear is cleared or treated. Surgery can improve otosclerosis and other conductive pathology. Some medicines aggravate tinnitus, and a review with the prescribing doctor sometimes resolves it. Somatic tinnitus, where the sound changes with jaw clenching or neck position, can respond to dental or physiotherapy treatment of the underlying disorder, though the trial evidence is thin and mostly low quality.
Pulsatile tinnitus is the clearest example of a treatable cause. A sound that beats in time with your pulse points to a vascular or venous source rather than the hearing system. Imaging can identify sigmoid sinus wall anomalies, dural arteriovenous fistulas, and related conditions, which can be corrected surgically or endovascularly in selected patients, often with the tinnitus stopping outright. This is why pulsatile tinnitus warrants investigation rather than reassurance.
Cochlear implantation has some of the strongest evidence for substantial and sometimes lasting tinnitus reduction in people who are appropriate implant candidates. A systematic review of 31 studies covering 479 patients with single-sided deafness found tinnitus reduced in almost every patient, sometimes completely, with stability out to 72 months in one cohort and no reported cases of tinnitus worsening. The implant is provided for the deafness, not for tinnitus alone, so this route applies only to people who meet candidacy criteria for implantation.
For most chronic tinnitus, there is no removable lesion. The sound accompanies cochlear damage and central changes in how the brain handles a reduced auditory signal, and no surgery addresses that.
What happens to tinnitus when nothing is done
The best data on the natural course comes from 388 chronic tinnitus patients at a tertiary clinic, re-surveyed after up to six years. Complete remission occurred in 3 patients (0.8%). Meaningful improvement in impact was far more common: 47% had dropped at least 7 points on the THI and 22% had dropped at least 20 points. Loudness, sound quality and which ear was affected stayed largely unchanged.
This pattern matters in chronic tinnitus. The tinnitus may persist, while its impact gradually reduces. This reduction in awareness and reaction is often described as habituation, and it is an important part of tinnitus management for many people.
Recent-onset tinnitus behaves differently. NICE guidance tells Audiologists and other health professionals to reassure patients that tinnitus is common and may resolve on its own, which is why the first weeks are managed with support and monitoring rather than intensive treatment, unless there is hearing loss or a red flag.
Psychological therapy has the strongest evidence base
A Cochrane review published in 2020 pooled 28 randomised trials and 2,733 adults. Against no intervention, cognitive behavioural therapy reduced the impact of tinnitus by about 11 points on the THI, rated low certainty. Against audiological care, the difference was 5.65 points, rated moderate certainty. Adverse effects were rare. The review’s main criticism is the lack of data at 6 and 12 months, so durability is not established.
Internet-delivered CBT performs comparably and costs less to deliver. A meta-analysis of 14 studies covering about 1,574 patients found average falls of 17.97 points on the THI and 24.56 points on the TFI, both large effects, with most of the gain still present at 12 months. For this reason, NICE recommends a stepped approach: digital CBT first, then group interventions, then individual therapy.
Mindfulness-based cognitive therapy outperformed relaxation training in a head-to-head trial. Among 75 patients, the mindfulness group scored 6.3 points better on tinnitus severity at the end of treatment and 7.2 points better at six months, with a number needed to treat of 6.9.
One trial deserves particular attention. The Tinnitus Retraining Therapy Trial randomised 151 patients to full TRT, partial TRT or standard of care and followed them for 18 months. The arms did not differ on the TFI, THI, or TQ. About half of participants in each arm achieved a clinically meaningful reduction. The takeaway for patients: careful audiological care with proper education and support did as much as the branded protocol.
Hearing aids and sound
Guidelines converge here. The AAO-HNS recommends a hearing aid evaluation for anyone with hearing loss and bothersome tinnitus. NICE recommends hearing aids where hearing loss affects communication, and advises against fitting amplification for tinnitus in people with normal hearing. Sound therapy and sound generators appear in guidelines as reasonable options with limited supporting evidence, reflecting small trials and inconsistent results.
The mechanism is mundane and useful. Restoring audibility of ambient sound reduces the contrast that makes tinnitus stand out in quiet. Benefit depends on how accurately the aids are fitted to your hearing loss, which is why real ear measurement is standard at every fitting at our practice, not an optional extra. Because we hold no manufacturer ownership and carry no brand targets, the aid recommended is the one that suits your hearing and your tinnitus.
Bimodal neuromodulation
Lenire pairs sound through headphones with mild electrical stimulation delivered to the tongue. It received TGA approval for use in Australia in September 2025, and The Audiology Place was part of the first group of Australian providers trained to offer Lenire as it became available in Australia.
The registration trial, TENT-A3, enrolled 112 patients, of whom 105 completed. Among participants with moderate or worse tinnitus, 58.6% met the 7-point THI threshold during bimodal treatment compared with 43.2% during sound-only treatment (p=0.022), and 45.5% met the 13-point TFI threshold compared with 29.6% (p=0.010). Across the full 12-week course, 79.4% of the whole cohort met the response threshold. The design was single-arm and could not be blinded, and the trial collected no data after treatment ended.
A retrospective review of 220 patients treated at a single United States clinic reported that 91.5% met the clinically meaningful threshold by about 12 weeks, with a mean THI fall of 27.8 points. That review was funded by the manufacturer, and its authors include a company consultant with a financial interest and a commercial provider of the treatment. The manufacturer also reports that 80% of participants in its first trial and 91% in its second sustained improvement for at least 12 months after treatment.
Read these numbers for what they measure. They describe how many people crossed a handicap threshold, not how many lost the sound. Outcomes vary between individuals, the trials assessed patients who met specific entry criteria, and candidacy is decided after assessment. Treatment involves a defined program of daily use with clinical review, and results cannot be predicted in advance for any one person.
What the guidelines advise against
The AAO-HNS advises health professionals not to prescribe antidepressants, anticonvulsants, anxiolytics or intratympanic medication for the primary purpose of treating persistent bothersome tinnitus. It advises against ginkgo biloba, melatonin, zinc and other dietary supplements, and against transcranial magnetic stimulation. NICE specifically states that betahistine should not be offered for tinnitus.
Drug development has a poor record. The most advanced recent candidate, OTO-313, failed its phase 2 trial in 2022 and the sponsor discontinued it. Nothing has replaced it in late-stage testing.
Medication still has a legitimate role. Depression, anxiety and insomnia occur frequently alongside tinnitus and are treated on their own merits by a GP or psychiatrist. The distinction is that the drug treats the mood or sleep disorder, not the tinnitus.
What is in development
A double-blind crossover trial at the University of Michigan tested a portable device delivering sound paired with precisely timed electrical stimulation of the neck and cheek in 99 patients with somatic tinnitus. More than 60% reported reduced symptoms after six weeks of active treatment, with no improvement during the sound-only control phase. The device is not approved or available in Australia. Neurofeedback, transcranial direct current stimulation and several drug candidates remain in early research.
The expert panel’s explanation for slow progress is worth knowing. Tinnitus mechanisms are still incompletely mapped, and tinnitus is probably several conditions sharing one symptom, which makes any single treatment look mediocre when tested across an unsorted group of patients.
Quality of life is the outcome that moves
Tinnitus severity tracks closely with mental health. In a cohort of 100 patients with chronic tinnitus attending an ENT clinic, 28% had moderate to severe depressive symptoms and 31% had moderate to severe anxiety symptoms, against roughly 6% to 7% in the general population. Handicap scores correlated with both depression (r=0.50) and anxiety (r=0.48), and patients with severe tinnitus had about three times the odds of clinically significant mood symptoms compared with those with mild tinnitus, after adjusting for age, sex and hearing status. Sleep disruption is the complaint patients most often raise first.
These numbers shift with treatment. Sleep, concentration, mood, and how much attention tinnitus takes up are all measurable. Many of the treatments with the strongest evidence aim to reduce tinnitus-related distress and improve sleep, concentration, emotional wellbeing and day-to-day function. This is why reputable tinnitus care focuses on meaningful improvement rather than promising that the sound will disappear.
Get checked promptly if any of these apply
Sudden hearing loss that develops over three days or less, has occurred within the past 30 days, and is not explained by an obvious outer or middle ear problem needs urgent assessment, because the treatment window for sudden sensorineural hearing loss is measured in days. Tinnitus that beats with your pulse, tinnitus in one ear only, and tinnitus with dizziness, facial weakness or other neurological symptoms all warrant medical assessment rather than watchful waiting. If tinnitus has you feeling unable to cope, tell your GP the same day, and if you need immediate support, Lifeline is available on 13 11 14.
Where an audiological assessment fits
Nobody can promise to cure chronic tinnitus. A diagnostic assessment answers the questions that shape what happens next: whether hearing loss is driving it, whether the pattern suggests a treatable cause, whether the sound needs imaging, and which evidence-based treatment fits your case. Our comprehensive tinnitus assessments run for 90 minutes, including extended high-frequency testing, because tinnitus often sits alongside hearing loss above the range a standard screening measures.
Book an assessment at The Audiology Place, Forestville or Epping, on (02) 9315 8327, or at theaudiologyplace.com.au.
References
- The current state of tinnitus diagnosis and treatment: a multidisciplinary expert perspective. Journal of the Association for Research in Otolaryngology, 2024.
- Jarach CM, et al. Global prevalence and incidence of tinnitus: a systematic review and meta-analysis. JAMA Neurology, 2022.
- Lewkowski K, et al. The prevalence of tinnitus in the Australian working population. Medical Journal of Australia, 2022.
- Fuller T, et al. Cognitive behavioural therapy for tinnitus. Cochrane Database of Systematic Reviews, 2020.
- Scherer RW, et al. Effect of tinnitus retraining therapy vs standard of care on tinnitus-related quality of life: a randomized clinical trial. JAMA Otolaryngology-Head and Neck Surgery, 2019.
- McKenna L, et al. Mindfulness-based cognitive therapy as a treatment for chronic tinnitus: a randomized controlled trial. Psychotherapy and Psychosomatics, 2017.
- Efficacy of internet-based therapies for tinnitus: a systematic review and meta-analysis of randomized controlled trials, 2024.
- The progression of chronic tinnitus over the years. Scientific Reports, 2021.
- Short- and long-term effect of cochlear implantation on disabling tinnitus in single-sided deafness patients: a systematic review. Journal of Clinical Medicine, 2022.
- Combining sound with tongue stimulation for the treatment of tinnitus: a multi-site single-arm controlled trial (TENT-A3). Nature Communications, 2024.
- Retrospective chart review demonstrating effectiveness of bimodal neuromodulation for tinnitus treatment in a clinical setting. Communications Medicine, 2025.
- Tunkel DE, et al. Clinical practice guideline: tinnitus. American Academy of Otolaryngology-Head and Neck Surgery Foundation, 2014.
- National Institute for Health and Care Excellence. Tinnitus: assessment and management. NICE guideline NG155, 2020.
- Bimodal auditory-somatosensory stimulation for somatic tinnitus, University of Michigan randomised trial, 2023.
- Psychiatric comorbidity in chronic tinnitus: depression and anxiety in an otolaryngology outpatient cohort, 2025.
The Audiology Place. Independent audiology, Forestville and Epping NSW. This article is general information and not a substitute for individual clinical assessment.
